Oncology and Hematology

Episodes 49-64 of 87

• 

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  RestartResume

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  MinuteCE®

  You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Management: The First FDA Approval for Patients

  RestartResume

  WHIM Syndrome Management: The First FDA Approval for Patients

  MinuteCE®

  WHIM Syndrome Management: The First FDA Approval for Patients

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit

• 

  MinuteCE®

  WHIM Syndrome (A Chronic Neutropenic Disorder): Uncouple the Complex for HCPs and Patients

  1.00 credit 7 episodes

  • 

    

    Jolan Walter, MD, PHD

  • 

    

    Teresa K. Tarrant, MD

  • 

    

    Peter E. Newburger, MD

  • 

    

    Jacob R. Bledsoe, MD

  1.00 credit 7 episodes

• 

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  RestartResume

  WHIM Syndrome: A Misguided Immune System!

  MinuteCE®

  WHIM Syndrome: A Misguided Immune System!

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  RestartResume

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  MinuteCE®

  Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)

  1.00 program credit

  • 

    

    Teresa K. Tarrant, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  RestartResume

  WHIM Syndrome: A Chronic Neutropenic Disorder

  MinuteCE®

  WHIM Syndrome: A Chronic Neutropenic Disorder

  1.00 program credit

  • 

    

    Peter E. Newburger, MD

  1.00 program credit

• 

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  RestartResume

  WHIM Syndrome Treatment: We Can Do Better!

  MinuteCE®

  WHIM Syndrome Treatment: We Can Do Better!

  1.00 program credit

  • 

    

    Jolan Walter, MD, PHD

  1.00 program credit

• 

  RestartResume

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  RestartResume

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  MinuteCE®

  Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

  RestartResume

  Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

  MinuteCE®

  Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  RestartResume

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  MinuteCE®

  How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

  1.25 program credits

  • 

    

    Yelena Janjigian, MD

  1.25 program credits

• 

  RestartResume

  Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

  RestartResume

  Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

  MinuteCE®

  Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

  1.25 program credits

  • 

    

    Samuel J. Klempner, MD

  1.25 program credits

• 

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  MinuteCE®

  Efficacy Data for Bispecific Antibodies in RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  RestartResume

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  MinuteCE®

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  MinuteCE®

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC

  RestartResume

  Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC

  MinuteCE®

  Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  RestartResume

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  RestartResume

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  MinuteCE®

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit